MYC and neoplasm: In sharp contrast to the oncogenic activity the PVT1 transcript demonstrates, a combination of 4C-seq, ATAC-seq and Hi-CHiP experiments has proven that promoter of PVT1 can act independently in breast cancer as a tumor suppressor by limiting c-MYC activity as it competes with the c-MYC promoter for a group of enhancers [80, 81].